• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Absence of Azole or Echinocandin Resistance in Candida glabrata Isolates in India despite Background Prevalence of Strains with Defects in the DNA Mismatch Repair Pathway.尽管印度存在背景流行的 DNA 错配修复途径缺陷菌株,但光滑念珠菌分离株中不存在唑类或棘白菌素耐药性。
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00195-18. Print 2018 Jun.
2
Spontaneous Mutational Frequency and Mutation Rates Vary by Echinocandin Agent against .棘白菌素类药物对. 的自发突变频率和突变率各不相同。
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01692-18. Print 2019 Jan.
3
Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.棘白菌素类药物(阿尼芬净、卡泊芬净和米卡芬净)对有和无 FKS 耐药突变的光滑念珠菌分离株的体内活性差异。
Antimicrob Agents Chemother. 2012 May;56(5):2435-42. doi: 10.1128/AAC.06369-11. Epub 2012 Feb 21.
4
Gene Point Mutations Are Not Antifungal Resistance Markers in .基因点突变不是. 的抗真菌耐药标志物。
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01876-18. Print 2019 Jan.
5
Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.临床光滑念珠菌分离株中米卡芬净和阿尼芬净的突变预防浓度和突变选择窗。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.01982-17. Print 2018 Mar.
6
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.棘白菌素类耐药性在光滑念珠菌中的增加:临床失败与 FKS 突变和最低抑菌浓度升高相关。
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
7
Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.棘白菌素和唑类药物治疗的中断导致克隆性光滑念珠菌持续性念珠菌血症中 FKS 改变的消失,但不导致唑类耐药性的出现。
Clin Microbiol Infect. 2016 Oct;22(10):891.e5-891.e8. doi: 10.1016/j.cmi.2016.07.025. Epub 2016 Jul 30.
8
In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.体外暴露于不断增加的米卡芬净浓度很容易促进光滑念珠菌分离株对棘白菌素产生耐药性。
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01542-16. Print 2017 Feb.
9
Anidulafungin Susceptibility Testing of Candida glabrata Isolates from Blood Cultures by the MALDI Biotyper Antibiotic (Antifungal) Susceptibility Test Rapid Assay.MALDI Biotyper 抗生素(抗真菌)药敏快速检测法检测血培养中光滑念珠菌分离株的阿尼达卢非尼药敏试验。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00554-19. Print 2019 Sep.
10
Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait.科威特临床光滑念珠菌分离株中抗真菌药物敏感性、棘白菌素类耐药的分子基础以及氟康唑耐药的分子流行病学。
Sci Rep. 2020 Apr 10;10(1):6238. doi: 10.1038/s41598-020-63240-z.

引用本文的文献

1
Antifungal drug resistance in Candida glabrata: role of cellular signaling and gene regulatory networks.光滑念珠菌的抗真菌药物耐药性:细胞信号传导和基因调控网络的作用
FEMS Yeast Res. 2025 Jan 30;25. doi: 10.1093/femsyr/foaf025.
2
Association of multilocus sequence typing, MSH2 gene mutations, and antifungal resistance in Candida glabrata: implications for clinical outcomes in Chinese hospitals.光滑念珠菌多位点序列分型、MSH2 基因突变与抗真菌耐药性的关系及其对中国医院临床结局的影响
Ann Clin Microbiol Antimicrob. 2024 Nov 8;23(1):100. doi: 10.1186/s12941-024-00758-4.
3
Candida glabrata (Nakaseomyces glabrata): A systematic review of clinical and microbiological data from 2011 to 2021 to inform the World Health Organization Fungal Priority Pathogens List.光滑念珠菌(Nakaseomyces glabrata):2011 年至 2021 年临床和微生物学数据的系统评价,为世界卫生组织真菌优先病原体清单提供信息。
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myae041.
4
Importance of the Mismatch Repair Protein Msh6 in Antifungal Resistance Development.错配修复蛋白Msh6在抗真菌耐药性发展中的重要性
J Fungi (Basel). 2024 Mar 12;10(3):210. doi: 10.3390/jof10030210.
5
The Microevolution of Antifungal Drug Resistance in Pathogenic Fungi.致病真菌中抗真菌药物耐药性的微观进化
Microorganisms. 2023 Nov 13;11(11):2757. doi: 10.3390/microorganisms11112757.
6
Epigenetic Regulation of Antifungal Drug Resistance.抗真菌药物耐药性的表观遗传调控
J Fungi (Basel). 2022 Aug 19;8(8):875. doi: 10.3390/jof8080875.
7
Drug Resistance and Evolvability in an Emerging Human Fungal Pathogen.新兴人类真菌病原体的耐药性和可进化性。
mBio. 2022 Oct 26;13(5):e0187622. doi: 10.1128/mbio.01876-22. Epub 2022 Aug 18.
8
Evolutionary Significance of Fungal Hypermutators: Lessons Learned from Clinical Strains and Implications for Fungal Plant Pathogens.真菌超突变体的进化意义:从临床株中学到的经验教训及其对真菌植物病原体的影响。
mSphere. 2022 Jun 29;7(3):e0008722. doi: 10.1128/msphere.00087-22. Epub 2022 May 31.
9
Molecular mechanisms underlying the emergence of polygenetic antifungal drug resistance in mismatch repair mutants of ..错配修复突变体中多基因抗真菌药物耐药性产生的分子机制
JAC Antimicrob Resist. 2022 Apr 7;4(2):dlac033. doi: 10.1093/jacamr/dlac033. eCollection 2022 Apr.
10
Tackling the emerging threat of antifungal resistance to human health.应对抗真菌耐药性对人类健康构成的新威胁。
Nat Rev Microbiol. 2022 Sep;20(9):557-571. doi: 10.1038/s41579-022-00720-1. Epub 2022 Mar 29.

本文引用的文献

1
A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance.一项针对印度 350 株假丝酵母菌(2009-17 年)抗真菌药敏模式的多中心研究:ERG11 和 FKS1 基因在唑类药物和棘白菌素类药物耐药中的作用。
J Antimicrob Chemother. 2018 Apr 1;73(4):891-899. doi: 10.1093/jac/dkx480.
2
Mismatch Repair of DNA Replication Errors Contributes to Microevolution in the Pathogenic Fungus .DNA 复制错误的错配修复有助于病原真菌的微进化。
mBio. 2017 May 30;8(3):e00595-17. doi: 10.1128/mBio.00595-17.
3
A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomes.秘鲁利马-卡亚俄念珠菌血流感染的多中心研究:菌种分布、抗真菌药物耐药性及临床结局
PLoS One. 2017 Apr 18;12(4):e0175172. doi: 10.1371/journal.pone.0175172. eCollection 2017.
4
Fluconazole and Echinocandin Resistance of Correlates Better with Antifungal Drug Exposure Rather than with Mutator Genotype in a French Cohort of Patients Harboring Low Rates of Resistance.在法国一个耐药率较低的患者队列中,氟康唑和棘白菌素耐药性与抗真菌药物暴露的相关性比与突变基因型的相关性更好。
Front Microbiol. 2016 Dec 23;7:2038. doi: 10.3389/fmicb.2016.02038. eCollection 2016.
5
Genetic Drivers of Multidrug Resistance in .……中多药耐药的遗传驱动因素
Front Microbiol. 2016 Dec 15;7:1995. doi: 10.3389/fmicb.2016.01995. eCollection 2016.
6
Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance.在真菌病原体光滑念珠菌中鉴定出的普遍存在的突变基因型促进了多药耐药性。
Nat Commun. 2016 Mar 29;7:11128. doi: 10.1038/ncomms11128.
7
Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria.德国和奥地利两家大学医院侵袭性光滑念珠菌分离株的棘白菌素耐药性及种群结构
Mycoses. 2016 May;59(5):312-8. doi: 10.1111/myc.12472. Epub 2016 Jan 25.
8
Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008-2014.棘白菌素类药物不敏感的光滑念珠菌血流感染的流行病学和危险因素:来自 2008-2014 年大型多地点基于人群的念珠菌血症监测计划的数据。
Open Forum Infect Dis. 2015 Dec 14;2(4):ofv163. doi: 10.1093/ofid/ofv163. eCollection 2015 Dec.
9
Incidence, characteristics and outcome of ICU-acquired candidemia in India.印度 ICU 获得性念珠菌血症的发生率、特征和结局。
Intensive Care Med. 2015 Feb;41(2):285-95. doi: 10.1007/s00134-014-3603-2. Epub 2014 Dec 16.
10
Drug-resistant Candida glabrata infection in cancer patients.癌症患者中的耐药光滑念珠菌感染。
Emerg Infect Dis. 2014 Nov;20(11):1833-40. doi: 10.3201/eid2011.140685.

尽管印度存在背景流行的 DNA 错配修复途径缺陷菌株,但光滑念珠菌分离株中不存在唑类或棘白菌素耐药性。

Absence of Azole or Echinocandin Resistance in Candida glabrata Isolates in India despite Background Prevalence of Strains with Defects in the DNA Mismatch Repair Pathway.

机构信息

Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.

Public Health Research Institute, Rutgers Biomedical and Health Sciences, Newark, New Jersey, USA.

出版信息

Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00195-18. Print 2018 Jun.

DOI:10.1128/AAC.00195-18
PMID:29610199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5971596/
Abstract

infections are increasing worldwide and exhibit greater rates of antifungal resistance than those with other species. DNA mismatch repair (MMR) gene deletions, such as , in resulting in a mutator phenotype have recently been reported to facilitate rapid acquisition of antifungal resistance. This study determined the antifungal susceptibility profiles of 210 isolates in 10 hospitals in India and investigated the impact of novel polymorphisms on mutation potential. No echinocandin- or azole-resistant strains and no mutations in hot spot regions were detected among the isolates, supporting our susceptibility testing results. CLSI antifungal susceptibility data showed that the MICs of anidulafungin (geometric mean [GM], 0.12 μg/ml) and micafungin (GM, 0.01 μg/ml) were lower and below the susceptibility breakpoint compared to that of caspofungin (CAS) (GM, 1.31 μg/ml). Interestingly, 69% of the strains sequenced contained six nonsynonymous mutations in , i.e., V239L and the novel mutations E459K, R847C, Q386K, T772S, and V239/D946E. Functional analysis of mutations revealed that 49% of the tested strains (40/81) contained a partial loss-of-function mutation. The novel substitution Q386K produced higher frequencies of CAS-resistant colonies upon expression in the mutant. However, expression of two other novel alleles, i.e., E459K or R847C, did not confer selection of resistant colonies, confirming that not all mutations in the MMR pathway affect its function or generate a phenotype of resistance to antifungal drugs. The lack of drug resistance prevented any correlations from being drawn with respect to genotype.

摘要

世界各地的感染正在增加,并且表现出比其他物种更高的抗真菌耐药率。最近有报道称,DNA 错配修复(MMR)基因缺失,如 ,导致突变体表型,有助于快速获得抗真菌耐药性。本研究确定了印度 10 家医院的 210 株 分离株的抗真菌药敏谱,并研究了新型 多态性对突变潜力的影响。在 分离株中未检测到棘白菌素或唑类耐药株,也未检测到热点区域的 突变,这支持了我们的药敏试验结果。CLSI 抗真菌药敏数据显示,阿尼达fungin(几何平均[GM],0.12 μg/ml)和米卡fungin(GM,0.01 μg/ml)的 MIC 值较低,低于卡泊fungin(CAS)(GM,1.31 μg/ml)的药敏折点。有趣的是,69%的 测序菌株在 中含有六个非同义突变,即 V239L 和新的突变 E459K、R847C、Q386K、T772S 和 V239/D946E。对 突变的功能分析表明,49%的测试菌株(40/81)含有部分功能丧失 突变。新型 取代 Q386K 在 突变体中表达时产生更高频率的 CAS 耐药菌落。然而,表达另外两个新的 等位基因,即 E459K 或 R847C,并没有赋予对 CAS 耐药菌落的选择,这证实了 MMR 途径中的并非所有突变都影响其功能或产生抗真菌药物耐药表型。缺乏耐药性阻止了与 基因型相关的任何相关性。